Zimmer Biomet lifts 2026 outlook and announces CFO exit
Zimmer Biomet raised its 2026 profit forecast after beating quarterly estimates on strong device demand. The firm also named an interim CFO to replace Suketu Upadhyay.
ZIMMER BIOMET HOLDINGS INC raised its 2026 adjusted profit forecast to $8.40–$8.55 per share following a first-quarter earnings beat. The medical device maker surpassed analyst estimates of $1.86 per share, reporting adjusted earnings of $2.09. Investors are weighing the earnings growth against the departure of CFO Suketu Upadhyay and a sales force reorganization.
Revenue rose to $2.087 billion, exceeding the $2.07 billion expected by analysts. The sports injury and fractures segment led growth with a 19.5% increase to $562.2 million. Hips business revenue rose 5.7% to $524.1 million, while the knee segment grew 4.5% to $828.6 million.
